Dabrafenib and Trametinib prolong coagulation through the inhibition of tissue factor in BRAFv600e mutated melanoma cells in vitro.

Cristian ScatenaSara FranceschiMaria FranziniChiara SanguinettiNadia RomitiLaura CaponiMario MandalàChiara Maria MazzantiAntonio Giuseppe Naccarato

Published in: Cancer cell international (2019)

The present study provides the first in vitro observation that tissue factor expressed in melanoma cells may contribute to the modulation of the coagulation state of patients in the treatment with BRAF inhibitors.

Keyphrases

end stage renal disease
ejection fraction
newly diagnosed
chronic kidney disease
prognostic factors
peritoneal dialysis
smoking cessation